Klaria Pharma Holding AB (publ.) Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Scott Boyer
Chief executive officer
SEK 1.6m
Total compensation
CEO salary percentage | 95.4% |
CEO tenure | 5.2yrs |
CEO ownership | 0.5% |
Management average tenure | no data |
Board average tenure | 5yrs |
Recent management updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -SEK 42m |
Jun 30 2024 | n/a | n/a | -SEK 45m |
Mar 31 2024 | n/a | n/a | -SEK 42m |
Dec 31 2023 | SEK 2m | SEK 2m | -SEK 36m |
Sep 30 2023 | n/a | n/a | -SEK 39m |
Jun 30 2023 | n/a | n/a | -SEK 45m |
Mar 31 2023 | n/a | n/a | -SEK 49m |
Dec 31 2022 | SEK 2m | SEK 2m | -SEK 64m |
Sep 30 2022 | n/a | n/a | -SEK 90m |
Jun 30 2022 | n/a | n/a | -SEK 89m |
Mar 31 2022 | n/a | n/a | -SEK 91m |
Dec 31 2021 | SEK 2m | SEK 2m | -SEK 54m |
Sep 30 2021 | n/a | n/a | -SEK 31m |
Jun 30 2021 | n/a | n/a | -SEK 30m |
Mar 31 2021 | n/a | n/a | -SEK 24m |
Dec 31 2020 | SEK 2m | SEK 2m | -SEK 51m |
Sep 30 2020 | n/a | n/a | -SEK 40m |
Jun 30 2020 | n/a | n/a | -SEK 34m |
Mar 31 2020 | n/a | n/a | -SEK 31m |
Dec 31 2019 | SEK 2m | SEK 2m | -SEK 22m |
Sep 30 2019 | n/a | n/a | -SEK 25m |
Jun 30 2019 | n/a | n/a | -SEK 24m |
Mar 31 2019 | n/a | n/a | -SEK 26m |
Dec 31 2018 | SEK 2m | SEK 2m | -SEK 27m |
Compensation vs Market: Scott's total compensation ($USD143.11K) is below average for companies of similar size in the Swedish market ($USD229.70K).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
CEO
Scott Boyer (62 yo)
5.2yrs
Tenure
SEK 1,589,000
Compensation
Mr. Scott Boyer is Director of Klaria Pharma Holding AB (publ.) from 2015 and also serves as Chief Executive Officer since October 25, 2023 and also served as Chief Scientific Officer from November 28, 201...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 10yrs | SEK 1.59m | 0.51% SEK 277.8k | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3yrs | SEK 200.00k | no data | |
Chairman | 5yrs | SEK 1.24m | 2.62% SEK 1.4m | |
Member of the Scientific Advisory Board | no data | no data | no data |
5.0yrs
Average Tenure
59.5yo
Average Age
Experienced Board: KLAR's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/05 04:49 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Klaria Pharma Holding AB (publ.) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kevin Sule | Redeye |
Ethel Szpilman Luvall | Redeye |